Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non -diabetic patients with chronic kidney disease (DIAMOND): A randomised, double-blind, crossover trial

Document Type

Article

Publication Date

7-1-2020

Keywords

SGLT2 inhibitor dapagliflozin, Proteinuria, Non-diabetic patients, Chronic kidney disease

Divisions

medicinedept

Funders

Diabetes Australian Research Trust Millennium Grant

Publication Title

Lancet Diabetes & Endocrinology

Volume

8

Issue

7

Publisher

Elsevier Science Inc

Publisher Location

STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA

This document is currently not available here.

Share

COinS